{"id":"as101-1-oral-solution","_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T04:54:59.528Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123614,"model":"claude-sonnet-4-5-20250929"},"description":"AS101 1% oral solution is an investigational small molecule immunomodulator being developed by Feramda. Currently in Phase 1 clinical development, this oral formulation is being evaluated for safety and tolerability, though specific therapeutic targets and indications have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT03216538","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Feramda","startDate":"2018-10-08","conditions":"Neovascular Age-related Macular Degeneration","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AS101 1% oral solution","genericName":"AS101 1% oral solution","companyName":"Feramda","companyId":"feramda","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}